Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jerome Baca

Physician Assistant, Medical Albuquerque, NM Physician Assistant

NPI 1811243462 CMS profile 10779229

6701 Jefferson St Ne, Albuquerque, NM 87109

Open in the dashboard

General payments

$2,932

69 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerome Baca of Albuquerque, NM is reported in the CMS Open Payments database as having received $2,932 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $670 17
2024 General $265 7
2023 General $1,125 23
2022 General $419 13
2021 General $453 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerome Baca
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jerome Baca were reported at $670. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jerome Baca Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $453 $156 $41–$563 $132
2022 $419 $185 $55–$649 $149
2023 $1,125 $199 $58–$717 $160
2024 $265 $206 $62–$740 $164
2025 $670 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,574 40 payments
  2. Olympus America Inc. $593 9 payments
  3. Calyxo, Inc. $209 4 payments
  4. Teleflex LLC $204 3 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $112 2 payments
  6. Boston Scientific Corporation $68 3 payments
  7. 180 Medical, Inc. $47 2 payments
  8. Urogen Pharma, Inc. $32 1 payment
  9. Inspire Medical Systems, Inc. $22 1 payment
  10. Endo Pharmaceuticals Inc. $21 1 payment
  11. Other $49 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,345 63 payments
  2. Travel and Lodging $560 5 payments
  3. Education $27 1 payment
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,574 40 payments
  2. iTIND System $443 6 payments
  3. CVAC ASPIRATION SYSTEM $209 4 payments
  4. UroLift System $204 3 payments
  5. CYSTO-NEPHRO VIDEOSCOPE $120 1 payment
  6. Nubeqa $112 2 payments
  7. OES CYSTONEPHROFIBERSCOPE $57 1 payment
  8. URETERO-RENO VIDEOSCOPE $57 1 payment
  9. HD CAMERA HEAD $53 1 payment
  10. XTANDI $36 2 payments
  11. Other $312 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

2,736

Median for Physician Assistant: 241

Drug cost

$92,479

Median for Physician Assistant: $4,110

Branded share of claims

13.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 41 $32,345
Tamsulosin Hcl Generic 1,328 $31,238
Finasteride Generic 566 $8,306
Testosterone Cypionate Generic 107 $6,775
Oxybutynin Chloride Er Oxybutynin Chloride Brand 158 $3,482
Doxazosin Mesylate Generic 157 $3,354
Solifenacin Succinate Generic 33 $1,395
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 91 $1,259
Terazosin Hcl Generic 57 $1,227
Tolterodine Tartrate Er Tolterodine Tartrate Brand 22 $948

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$63,384

Medicare's payments for the services billed

Medicare patients

614

Average age 74

Services billed

1,330

84 women, 530 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 45%
Diabetes 30%
Ischemic heart disease 30%
Chronic kidney disease 23%
Atrial fibrillation 16%
COPD 14%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record